Top Page
Shanghai Pharmaceuticals Holding Co
(2607)
Shanghai Pharmaceuticals Holding Co (2607) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai Pharmaceuticals Holding Co Business Overview & Revenue Model
Shanghai Pharmaceuticals Holding Co Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 287.50B | 275.25B | 260.30B | 231.98B | 215.82B | 191.91B |
| Gross Profit | 30.57B | 30.63B | 30.93B | 30.49B | 28.54B | 27.44B |
| EBITDA | 8.89B | 12.06B | 10.90B | 12.44B | 10.55B | 10.44B |
| Net Income | 5.71B | 4.55B | 3.77B | 5.62B | 5.09B | 4.50B |
Balance Sheet | ||||||
| Total Assets | 258.76B | 221.21B | 211.97B | 198.13B | 163.44B | 149.19B |
| Cash, Cash Equivalents and Short-Term Investments | 48.69B | 44.38B | 40.67B | 37.01B | 22.39B | 22.30B |
| Total Debt | 67.33B | 47.79B | 42.90B | 38.56B | 31.69B | 31.79B |
| Total Liabilities | 160.80B | 137.47B | 131.65B | 120.13B | 104.37B | 94.44B |
| Stockholders Equity | 82.83B | 71.68B | 68.52B | 67.06B | 49.36B | 45.35B |
Cash Flow | ||||||
| Free Cash Flow | 3.51B | 3.43B | 2.26B | 2.06B | 942.55M | 3.83B |
| Operating Cash Flow | 2.71B | 5.83B | 5.23B | 4.74B | 5.06B | 6.84B |
| Investing Cash Flow | -779.17M | 415.98M | -2.49B | ― | ― | ― |
| Financing Cash Flow | -1.05B | -1.86B | 231.85M | 12.14B | 1.57B | ― |
Shanghai Pharmaceuticals Holding Co Technical Analysis
Shanghai Pharmaceuticals Holding Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$64.16B | 8.73 | 8.74% | 3.75% | -2.68% | -21.45% | |
71 Outperform | HK$65.80B | 7.27 | 7.53% | 2.67% | 2.77% | 39.24% | |
62 Neutral | HK$4.05B | 21.55 | 5.07% | 3.81% | 0.33% | -44.28% | |
60 Neutral | HK$786.24M | 15.08 | 8.12% | 8.03% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Shanghai Pharmaceuticals Holding Co Corporate Events
Shanghai Pharmaceuticals Holding Co., Ltd., a leading Chinese pharmaceutical manufacturer and distributor, focuses on the production and sale of a broad range of medicines and healthcare products for hospitals, pharmacies and other healthcare institutions in China and abroad. The company operates across the pharmaceutical value chain, leveraging its scale and network to support a diversified portfolio of drug products and related services.
The company has formally executed its 2026 Sales and Procurement Framework Agreement with Yunnan Baiyao, effective for the full year from 1 January to 31 December 2026, on terms consistent with those previously disclosed. The confirmation of this continuing connected transaction secures a defined framework for mutual sales and procurement between the two pharmaceutical groups for 2026, providing visibility over future business volumes and reinforcing Shanghai Pharmaceuticals’ commercial ties with a key sector partner, while the company states that all other previously announced information related to the arrangement remains unchanged.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals announced the completion of an equity adjustment involving the transfer of the entire equity interest in Shanghai Industrial Investment (Holdings) Co. (SIIC) from its de facto controller, Shanghai SASAC, to Golden Bell, confirming that the transaction does not alter the company’s controlling shareholder structure or the identity of its ultimate controller. Following the completion of the adjustment and the latest share purchase plan, SIIC and its subsidiaries now hold 498,588,000 A and H shares, representing 13.45% of the company’s issued share capital, signalling a consolidated but stable ownership position that preserves governance continuity for investors and other stakeholders.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding has secured board approval to renew its sales and procurement framework arrangement with substantial shareholder Yunnan Baiyao for another year, setting up a 2026 framework under which the two groups will continue to trade a broad range of medicines, medical devices, healthcare products, food products, and TCM-related items. Although the 2026 framework agreement is not yet executed, it will run from 1 January to 31 December 2026 and allows members of both groups to sign individual implementation contracts within annual caps, with the transactions classified as continuing connected transactions under Hong Kong listing rules, triggering reporting, annual review, and announcement obligations but exempting the company from circular and independent shareholders’ approval requirements.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced an interim cash dividend of RMB 1.2 per 10 shares for the six months ending June 30, 2025, with an ex-dividend date of December 29, 2025. This announcement reflects the company’s ongoing commitment to shareholder returns and may influence its market positioning by highlighting its financial health and strategic focus on rewarding investors.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. has established implementation rules for its Audit Committee to strengthen the decision-making function of its Board of Directors and ensure effective supervision over management. The Audit Committee is tasked with overseeing the relationship with external auditors, reviewing financial information, and supervising the company’s financial reporting, risk management, and internal control systems. This move is expected to enhance the company’s corporate governance and ensure diligent financial oversight.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. held its second extraordinary general meeting of 2025, where key resolutions were passed, including the abolishment of the Supervisory Board and amendments to the Articles of Association. The meeting, which adhered to the legal requirements of the People’s Republic of China, saw significant shareholder participation, with a high percentage of votes in favor of the proposed changes, indicating strong support for the company’s strategic direction.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. announced an interim dividend of RMB 1.2 per 10 shares for the six months ending June 30, 2025, with payment to be made in Hong Kong dollars. The announcement includes details on withholding tax rates applicable to various shareholder categories, impacting both enterprise and individual non-resident shareholders. This move reflects the company’s ongoing commitment to shareholder returns and may influence investor sentiment positively.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced the convening of an Extraordinary General Meeting on December 9, 2025, due to insufficient shareholder voting shares to meet the required threshold. This meeting will address key matters as outlined in the company’s notice and circular, potentially impacting the company’s governance and strategic decisions.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced an interim cash dividend of RMB 1.2 per 10 shares for the six months ending June 30, 2025. This update includes the date for shareholders’ approval set for December 9, 2025, but other details such as the payment date and exchange rate remain to be announced, reflecting the company’s ongoing commitment to shareholder returns.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced an Extraordinary General Meeting (EGM) scheduled for December 9, 2025, to discuss significant changes including the abolishment of the Supervisory Board and amendments to the Articles of Association. These proposals, if approved, could streamline the company’s governance structure and potentially impact its operational efficiency and shareholder engagement.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. announced proposed amendments to its Articles of Association and the abolishment of its Supervisory Board, replacing it with an audit committee. These changes align with recent revisions in Chinese corporate and securities laws, aiming to streamline governance and enhance operational efficiency. The amendments are expected to impact the company’s governance structure, potentially influencing its market positioning and stakeholder relations.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. announced the renewal of its Procurement Framework Agreement with Wing Fat Printing, effective from January 1, 2026, to December 31, 2026. This agreement allows Wing Fat Group to continue supplying printed packaging materials for pharmaceutical products, ensuring the stability of Shanghai Pharmaceuticals’ operations and meeting future demand. The transactions are classified as continuing connected transactions under the Listing Rules, subject to specific reporting and review requirements but exempt from circular and independent shareholders’ approval. The annual cap for these transactions is set at RMB90,000,000, based on estimated future demand and historical procurement amounts. The agreement is expected to benefit the company by reducing administrative costs and maintaining business stability.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. has released its third quarterly report for 2025, prepared in accordance with PRC Accounting Standards for Business Enterprises. The report, which has not been audited, emphasizes the company’s commitment to transparency and accuracy in its financial disclosures, as affirmed by its board of directors and senior management. This announcement underscores the company’s adherence to regulatory requirements and its ongoing efforts to maintain trust with stakeholders.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced its proposed 2025 Interim Profit Distribution Plan, which was approved by the board of directors. The company plans to distribute a cash dividend of RMB1.20 per ten shares, amounting to a total of RMB445,003,417.08, representing 9.98% of the consolidated net profit for the first half of 2025. This plan is contingent upon shareholder approval at the upcoming general meeting. The announcement reflects the company’s commitment to returning value to its shareholders and maintaining stable financial operations.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. announced an interim cash dividend of RMB 1.2 per 10 shares for the six months ending June 30, 2025. This announcement reflects the company’s ongoing commitment to returning value to its shareholders and may influence its market positioning by showcasing financial stability and shareholder confidence.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced a board meeting scheduled for October 30, 2025, to approve the company’s third-quarter results and consider interim dividend payments. This meeting is significant as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
Shanghai Pharmaceuticals Holding Co., Ltd. announced an equity adjustment involving the transfer of the entire equity interest in Shanghai Industrial Investment (Holdings) Company Limited to Golden Bell International Holdings Limited. This adjustment increases the shareholding of Shanghai Shangshi (Group) Co., Ltd. from 25.303% to 38.487% without changing the company’s controlling shareholder or de facto controller, which remains Shanghai SASAC. The adjustment complies with relevant regulations, exempting the acquirer from a mandatory tender offer, and does not trigger any mandatory general offer obligations under Hong Kong’s Code on Takeovers and Mergers.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$13.50 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.